{"title":"乳腺转移性癌的化疗。四种药物治疗方案。","authors":"W Mattsson, I Gynning, C Tropé, B Astedt","doi":"10.3109/02841867709134300","DOIUrl":null,"url":null,"abstract":"<p><p>Combination chemotherapy (vincristine, adriamycin, cyclophosphamide, methotrexate with leucoverin rescue) in 32 patients with metastatic carcinoma of the breast resulted in an overall response rate of 81 per cent (9/32 complete remission, 17/32 partial remission). No serious side effects were noted. Karnofsky performance index improved in 24/26 responders.</p>","PeriodicalId":7139,"journal":{"name":"Acta radiologica: therapy, physics, biology","volume":"16 2","pages":"97-108"},"PeriodicalIF":0.0000,"publicationDate":"1977-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/02841867709134300","citationCount":"1","resultStr":"{\"title\":\"Chemotherapy of metastatic carcinoma of the breast. A 4-drug regimen.\",\"authors\":\"W Mattsson, I Gynning, C Tropé, B Astedt\",\"doi\":\"10.3109/02841867709134300\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Combination chemotherapy (vincristine, adriamycin, cyclophosphamide, methotrexate with leucoverin rescue) in 32 patients with metastatic carcinoma of the breast resulted in an overall response rate of 81 per cent (9/32 complete remission, 17/32 partial remission). No serious side effects were noted. Karnofsky performance index improved in 24/26 responders.</p>\",\"PeriodicalId\":7139,\"journal\":{\"name\":\"Acta radiologica: therapy, physics, biology\",\"volume\":\"16 2\",\"pages\":\"97-108\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1977-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.3109/02841867709134300\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta radiologica: therapy, physics, biology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3109/02841867709134300\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta radiologica: therapy, physics, biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3109/02841867709134300","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Chemotherapy of metastatic carcinoma of the breast. A 4-drug regimen.
Combination chemotherapy (vincristine, adriamycin, cyclophosphamide, methotrexate with leucoverin rescue) in 32 patients with metastatic carcinoma of the breast resulted in an overall response rate of 81 per cent (9/32 complete remission, 17/32 partial remission). No serious side effects were noted. Karnofsky performance index improved in 24/26 responders.